2. Immunology/Inflammation Apoptosis
  3. PD-1/PD-L1 Apoptosis
  4. Adebrelimab

Adebrelimab  (Synonyms: SHR-1316)

Art. -Nr.: HY-P99422 Reinheit: 99.06%
COA
SDS
Technical Support

Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr. : 2247114-85-6

Größe Preis Verfügbarkeit Menge
1 mg Auf Lager
5 mg Auf Lager
10 mg Auf Lager
50 mg   Angebot einholen  
100 mg   Angebot einholen  

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Adebrelimab Related Antibodies

Top Publications Citing Use of Products

  • Biologische Aktivität

  • Reinheit & Dokumentation

  • Verweise

  • Kundenbewertung

Beschreibung

Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC)[1][2].

Isotype

Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

B7-H1/PD-L1/CD274
In Vitro

Adebrelimab (SHR-1316; 0.06-1mg/mL; 48 hours) inhibits effects on the cell proliferation, migration, invasion of SK-BR-3 and AU565 cells[1].
Adebrelimab (SHR-1316; 0.1-1mg/mL; 48 hours) downregulateds the expression of PD-L1, p-PI3K, p-AKT and upregulates the expression FOXO1[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Adebrelimab Related Antibodies

Cell Viability Assay[1]

Cell Line: SK-BR-3 and AU565 cells
Concentration: 0.06 mg/mL, 0.13 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 1 mg/mL
Incubation Time: 48 hours
Result: The viability of SK-BR-3 and AU565 cells decreased gradually.

Apoptosis Analysis[1]

Cell Line: SK-BR-3 and AU565 cells
Concentration: 0.1 mg/mL, 1 mg/mL
Incubation Time: 48 hours
Result: Promoted cell apoptosis.

Cell Migration Assay [1]

Cell Line: SK-BR-3 and AU565 cells
Concentration: 0.1 mg/mL, 1 mg/mL
Incubation Time: 48 hours
Result: Decreased the migration rate of SK-BR -3 and AU565 cells.

Western Blot Analysis[1]

Cell Line: SK-BR-3 and AU565 cells
Concentration: 0.1 mg/mL, 1 mg/mL
Incubation Time: 48 hours
Result: Downregulated the expression of PD-L1, p-PI3K, p-AKT and upregulated the expression FOXO1.
In Vivo

Adebrelimab (SHR-1316; 200 μg; three times a week; for 21 days) shows inhibition effects on tumor growth[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Pathogen free (SPF) BALB/c nude female mice (aged 5-6 weeks) injected with SK-BR-3 cells[1]
Dosage: 200 μg
Administration: Three times a week; for 21 days
Result: Significantly inhibited tumor growth.
Klinische Studie
Gene ID

29126  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molekulargewicht

145.56 kDa

CAS. Nr.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Adebrelimab]
Versand

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG4 kappa
Biological Activity
  • Flow cytometric analysis of 1.5X106 MDA-MB-231 cells labeling Adebrelimab (HY-P99422, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • Immobilized HuPD-L1-hFc can bind Adebrelimab. The EC50 for this effect is 4.213 ng/mL.
Reinheit & Dokumentation
Verweise
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Adebrelimab Related Classifications

  • Molaritätsrechner

  • Verdünnungsrechner

Die Formel zur Berechnung von Molaritäten

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)

Diese Gleichung wird häufig abgekürzt als: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Adebrelimab2247114-85-6SHR-1316SHR1316SHR 1316PD-1/PD-L1ApoptosisPD-1/Programmed death-ligand 1PD-L1 antibodyantitumor activityp-PI3Kp-AKTFOXO1Inhibitorinhibitorinhibit

Ihre kürzlich angesehenen Produkte:

Online-Anfrage

Your information is safe with us. * Required Fields.

Produktname

  

Requested Quantity *

Name des Antragstellers *

 

Anrede

E-Mail-Addresse *

 

Telefonnummer *

Department

 

Name der Organisation *

City

Bundesland

Country or Region *

      

Bemerkungen

Massenanfrage

Inquiry Information

Produktname:
Adebrelimab
Art. -Nr.:
HY-P99422
Menge:
MCE Japan Authorized Agent:

Kundenbewertung

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Produktname

  

Lot #

Name des Antragstellers *

 

E-Mail-Addresse *

Telefonnummer

 

Department *

Name der Organisation *

 

Country or Region *

Bemerkungen

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.